KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CareDx (CDNA) Research & Development (2016 - 2026)

CareDx's Research & Development history spans 14 years, with the latest figure at $21.4 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 15.61% to $21.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $74.3 million, a 2.76% increase, with the full-year FY2025 number at $71.4 million, down 1.49% from a year prior.
  • Research & Development hit $21.4 million in Q1 2026 for CareDx, up from $19.3 million in the prior quarter.
  • Over the last five years, Research & Development for CDNA hit a ceiling of $24.4 million in Q1 2023 and a floor of $16.6 million in Q4 2024.
  • Historically, Research & Development has averaged $19.9 million across 5 years, with a median of $19.3 million in 2025.
  • Biggest five-year swings in Research & Development: surged 36.72% in 2022 and later dropped 23.18% in 2024.
  • Tracing CDNA's Research & Development over 5 years: stood at $23.6 million in 2022, then dropped by 20.11% to $18.8 million in 2023, then dropped by 11.74% to $16.6 million in 2024, then rose by 16.16% to $19.3 million in 2025, then increased by 10.93% to $21.4 million in 2026.
  • Business Quant data shows Research & Development for CDNA at $21.4 million in Q1 2026, $19.3 million in Q4 2025, and $16.8 million in Q3 2025.